Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. - Wikidata - wikimedia - TriplyDB

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

http://www.wikidata.org/entity/Q41224253

about

Development of New Deoxycytidine Kinase Inhibitors and Noninvasive in Vivo Evaluation Using Positron Emission Tomography Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography The Proportion of Malignancy in Incidental Thyroid Lesions on 18-FDG PET Study: A Systematic Review and Meta-analysis.Positron emission tomography and colorectal cancer.Developments in imaging. An historical review.Single amino acid chelates (SAAC): a strategy for the design of technetium and rhenium radiopharmaceuticals.The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT.Low dose of 2-deoxy-D-glucose kills acute lymphoblastic leukemia cells and reverses glucocorticoid resistance via N-linked glycosylation inhibition under normoxia.Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer.Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.Anti-Angiogenic/Vascular Effects of the mTOR Inhibitor Everolimus Are Not Detectable by FDG/FLT-PET Does 18F-FDG positron emission tomography-computed tomography have a role in initial staging of hepatocellular carcinoma?Ketogenic diets as an adjuvant cancer therapy: History and potential mechanism Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients.18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma.The role of positron emission tomography in the management of colorectal cancer.Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization.The role of FDG PET/CT in evaluation of mediastinal masses and neurogenic tumors of chest wall.Diagnostic value for extrahepatic metastases of hepatocellular carcinoma in positron emission tomography/computed tomography scan.Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma.MRI of High-Glucose Metabolism Tumors: a Study in Cells and Mice with 2-DG-Modified Superparamagnetic Iron Oxide Nanoparticles.Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy.Application of positron emission tomography imaging to cancer screening.FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study.Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.Use of benzodiazepines before (18)F-FDG-PET/CT dual-phase imaging does not decrease the efficacy of the study.Is early response by (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?Mitochondria-mediated energy adaption in cancer: the H(+)-ATP synthase-geared switch of metabolism in human tumors.Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma.FDG-PET/CT finding of benign metastasizing leiomyoma of the lung.The role of positron emission tomography in the management of non-small cell lung cancer.Imaging 'the lost tribe': a review of adolescent cancer imaging. Part 1.A novel aliphatic 18F-labeled probe for PET imaging of melanoma.Intraductal papillary mucininous neoplasm of the bile ducts: multimodality assessment with pathologic correlation.The role and future potential of fluorinated biomarkers in positron emission tomography.Biomarker studies on radiotherapy to hepatocellular carcinoma.(99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials.Evolution of lymphoma staging and response evaluation: current limitations and future directions.Molecular imaging of tumors and metastases using chemical exchange saturation transfer (CEST) MRI.

P2860

Q27679693-1B9BBD22-92DA-462E-B5B6-A92A40256D2D Q28354052-BE4AE770-3126-4CE7-A18C-7A77691ECF2A Q31159316-0E29D8FF-641F-431C-869A-DF189515463F Q31893861-1829C6D5-AB03-49DB-9A96-07BB96206954 Q33179928-394E9161-3B99-469D-ABA3-840AB7EA0328 Q33417714-E5DB0443-1D54-4B60-BFFD-5DFE5D279E05 Q33704152-5DADD7DB-D25C-4F7C-A6C7-113E030C4A17 Q33761600-2C259920-E053-474E-A70C-F215A3475FCA Q33790538-306F645F-8A90-4209-9002-8DE70D023514 Q33919290-9F5848C5-4AE1-44A3-AE27-D1FD85F9ED91 Q33995787-8CAC2E95-BCF8-4AAD-BF39-74835CD0E44A Q34041370-886E7956-FE69-482C-A300-628C9E272BCE Q34083775-11D4976E-F037-40A3-B480-97FDDEE6F781 Q34432306-9DE45246-8241-4F5C-BA4E-6C1B83EC6858 Q34747081-CC3B7844-B3CD-43D1-A398-5EBC6ACEFEF3 Q35595395-8F1D6ACC-C3D8-4744-B696-027A60A60212 Q35615005-AAB41A56-85AA-4895-809E-CE96869048A6 Q35626234-BB923F4F-66FC-4708-BFB0-BC551CA73733 Q36046502-8657479C-96BA-476F-A993-C48EAF1DFB6F Q36049920-E6F74977-1451-4DE9-B598-F2409A451E9D Q36285607-A8FDF221-3999-4027-BD79-D54B230EA6B9 Q36488378-AA5C2468-570F-4AB3-8CB9-C61E5C78D178 Q36610698-D3235140-1646-4C7C-AF37-31A2413D6CE6 Q36621633-E5943554-33FC-48B9-BA9B-B89EE6076009 Q36641933-26D85500-A8A2-4332-99AD-B430457B0152 Q36731426-ECEB56F7-A9F5-45C4-B1DE-C651CE86E6E0 Q36771789-1B5F960C-E018-421E-8EED-D87112CC93EB Q36936979-20EC091E-5C01-4EC5-B55C-082ED42FFF63 Q36953477-B11682A1-AC43-4ABF-ADB5-32F6098F1732 Q37068011-BA2F8481-9D57-4977-A4C3-ABF06357620E Q37082544-1FE21CFF-E557-4865-86F8-D828D70F797A Q37210598-D910D83F-DCA2-4615-99E4-0FF333BF38DF Q37471540-A93BD6A8-1177-4FE3-91F0-8A6C11DA672C Q37624536-09F8ED0D-6B57-4833-B540-7781BC3D42CB Q37801557-AFAA9BBD-D394-42C1-A1C7-F87A1A8F6B4D Q38028536-1DFEFE9D-55EB-4F53-B452-69E0E3B74CEF Q38083433-FC67C223-1353-40D3-87D3-E9CA562188C0 Q38566895-B6075EC1-4156-4609-8A5E-6603247BC3B0 Q38671671-6F759845-5490-4DBB-B164-DC752D15F00F Q39070989-31063177-DE32-49CB-991F-75D5947CA06E

P2860

Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

http://www.wikidata.org/entity/Q41224253

description

1996 nî lūn-bûn

@nan

1996年の論文

@ja

1996年論文

@yue

1996年論文

@zh-hant

1996年論文

@zh-hk

1996年論文

@zh-mo

1996年論文

@zh-tw

1996年论文

@wuu

1996年论文

@zh

1996年论文

@zh-cn

name

Oncological applications of po ...... luorine-18 fluorodeoxyglucose.

@en

type

label

Oncological applications of po ...... luorine-18 fluorodeoxyglucose.

@en

prefLabel

Oncological applications of po ...... luorine-18 fluorodeoxyglucose.

@en

P1433

Q41224253-74673737-14DF-47A7-9712-CBD0842A406B

P1476

Q41224253-89FA3B83-ADD8-44BE-8533-85EDE69F708D

P2093

Q41224253-0D36982E-1C2A-4DEA-907F-48925231B674

Q41224253-288DF4B5-C013-4383-BF7A-3397C5C0E6FC

Q41224253-3164D2CB-19BF-4B7F-B534-688F13F5E14A

Q41224253-4241867B-009D-46D4-8E9A-BC6B5FBC20B5

Q41224253-44B37A9E-2A74-4289-B4D3-C3A04C02F2CE

Q41224253-73D1DD9D-CE2E-494E-A425-D1CA39DC1191

Q41224253-B5A681DB-22D5-4DD5-AF33-DC0C35199A19

Q41224253-C50E51EE-09DA-4BDD-80C6-558B5E05D3B6

P2860

Q41224253-0811E109-F6C5-42F7-BA27-16DEEC77222E

Q41224253-09CA1F01-4371-47E2-A238-7D0EB14BCEE4

Q41224253-0DBAA785-5375-4B12-92F2-1F1E20C3E576

Q41224253-13B59590-63A4-4F4A-99CA-BF65A801872E

Q41224253-1C42B4A9-6ED9-4EC2-984C-CD8B309C0240

Q41224253-1D56BA2D-FA68-444B-9F35-B25BD8B4CA0A

Q41224253-291881D2-CC11-46DC-81FF-C13F371AEF8E

Q41224253-3A27DF81-B9BE-4D0F-9869-5B1A7768DDA2

Q41224253-3CE08523-CB0B-4750-B62F-10BADAE57707

Q41224253-41F42AEB-3E44-4733-A3E0-4E1CECB0A921

P2888

Q41224253-5D9CD98B-1B4F-4768-90DB-8DC4809EB82E

P304

Q41224253-6C056974-6E28-4D87-8AE1-E77BA491AE8D

P31

Q41224253-953F795A-DB53-4606-94E4-DA1A85FA2C6C

P356

Q41224253-09AC2A96-B02D-4916-BEC6-4BDD65F7107B

P433

Q41224253-05FE019C-7B29-4084-AE0B-25128FCD9D4E

P478

Q41224253-EA79C191-761F-4DE1-BBE9-A88D21065886

P577

Q41224253-92C1773E-9912-4E81-92BC-9F573A0E147A

P698

Q41224253-095B7EB7-9897-4C18-98E8-79466966D219

P356

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Oncological applications of po ...... luorine-18 fluorodeoxyglucose.

@en

P2093

B J Kaschten

http://www.w3.org/2001/XMLSchema#string

G Jerusalem

http://www.w3.org/2001/XMLSchema#string

J Foidart-Willems

http://www.w3.org/2001/XMLSchema#string

P Paulus

http://www.w3.org/2001/XMLSchema#string

P Rigo

http://www.w3.org/2001/XMLSchema#string

R Hustinx

http://www.w3.org/2001/XMLSchema#string

T Benoit

http://www.w3.org/2001/XMLSchema#string

T Bury

http://www.w3.org/2001/XMLSchema#string

P2860

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations

Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.

Positron emission tomography applied in the study of pituitary adenomas.

New methods for imaging the breast: techniques, findings, and potential.

Hepatic metastases: basic principles and implications for radiologists.

Preoperative staging of non-small-cell carcinoma of the lung: imaging methods.

4-Borono-2-[18F]fluoro-D,L-phenylalanine: a possible tracer for melanoma diagnosis with PET.

Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose.

Breast cancer: PET imaging of estrogen receptors.

Prediction of survival in glioma patients by means of positron emission tomography.

P2888

P304

1641-1674

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/BF01249629

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

1996-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

8929320

http://www.w3.org/2001/XMLSchema#string